

Manual Title Pharmacy Manual	Chapter App. D	Page 0
Chapter Subject Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, and Drug Utilization Review Board Service Authorization Changes	Page Revision Date <u>TBD</u>	

DRAFT

Manual Title	Chapter	Page
Pharmacy Manual	App. D	1
Chapter Subject	Page Revision Date	
Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, and Drug Utilization Review Board Service Authorization Changes	<u>TBD</u>	

PREFERRED DRUG LIST / COMMON CORE FORMULARY CHANGES, 90 DAY SUPPLY LIST CHANGES, AND DRUG UTILIZATION REVIEW BOARD SERVICE AUTHORIZATION CHANGES

The following ~~updates new drugs and service authorization criteria~~ were recently ~~reviewed~~~~decommended~~ and approved by the Drug Utilization Review Board ~~and the DMAS Pharmacy and Therapeutics (P&T) Committee on June 2, 2022 and September 8, 2022.~~

These changes, along with a complete listing of preferred drugs and service authorization requirements, are posted on the Virginia Medicaid Pharmacy Services Portal at:

<https://www.virginiamedicaidpharmacyservices.com/provider>

Effective immediately, the following drugs require a service authorization (SA). SA forms can be found at:

<https://www.virginiamedicaidpharmacyservices.com/provider/authorizations>

- ~~Besremi[®] (ropeginterferon alfa-2b-njft)~~
- ~~Livtencity[™] (maribavir)~~
- ~~Seemblemix[®] (asciminib)~~
- ~~Tavneos[™] (avacopan)~~
- ~~Voxzogo[™] (vosoritide)~~
- ~~Exkivity[™] (mobocertinib)~~
- ~~Kerendia[®] (finerenone)~~
- ~~Welireg[™] (belzutifan)~~
- ~~Fotivda[®] (tivozanib)~~
- ~~Lumakras[™] (sotorasib)~~
- ~~Myfembree[®] (relugolix, estradiol, and norethindrone acetate)~~
- ~~Truseltiq[™] (infigratinib)~~
- ~~Wegovy[™] (semaglutide)~~ ~~Camzyos[™] (mavacamten)~~
- ~~Vijoice[®] (alpelisib)~~
- ~~Vonjo[™] (pacritinib)~~
- Rezurock[™] (belumosudil)

Manual Title	Chapter	Page
Pharmacy Manual	App. D	2
Chapter Subject	Page Revision Date	
Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, and Drug Utilization Review Board Service Authorization Changes	<u>TBD</u>	

The DMAS P&T Committee conducted its annual review of the following PDL Phase II drug classes and reviewed new drugs in PDL Phase I on ~~March 17, 2022~~ September 22, 2022.

On ~~July-January 1, 2023~~, the following changes, and additions to the Preferred Drug List (PDL) will be effective.

Virginia Preferred Drug List Changes Effective July 1 <u>January 1, 2023</u>		
Drug Class	Preferred	Non-Preferred (requires SA)
<u>Acne Agents, Topical</u>		<u>Twynéo[®]</u>
<u>Alzheimer's Agents</u>	<u>Rivastigmine (transdermal) (generic for Exelon[®])</u>	<u>Exelon[®] (transdermal)</u>
<u>Antibiotics – Inhaled</u>	<u>Tobramycin neb (generic for Tobi[®])</u>	
<u>Anticonvulsants</u>	<u>Lacosamide sol, tab (Generic for Vimpat[®])</u>	<u>Vimpat[®] sol, tab</u>
<u>Antihypertensives, Sympatholytics</u>	<u>Clonidine transdermal (generic for Catapres-TTS[®])</u>	
<u>Bronchodilators</u>	<u>Arformoterol (AG for Brovana[®])</u>	
<u>Diabetes Agents – Insulins</u>		<u>Insulin glargine (generic for Lantus[®] and Lantus Solostar[®])</u>
<u>Epinephrine, Self-injected</u>	<u>EpiPen[®] EpiPen Jr[®]</u>	<u>Epinephrine (Generic for EpiPen Jr[®])</u>
<u>GLUCAGON AGENTS</u>	<u>Baqsimi[™] Glucagon emergency kit (Fresenius) Gvoke[®] Proglycem[®]</u>	<u>Diazoxide Glucagon emergency kit (Lilly) Zegalogue[®]</u>
<u>HEMOPHILIA TREATMENTS</u>	<u>All agents</u>	
<u>Immunomodulators, Atopic Dermatitis</u>	<u>Dupixent[®]</u>	
<u>Nasal Steroids</u>		<u>Nasonex[™] OTC</u>
<u>Opioids – Short Acting</u>		<u>Tramadol soln (generic for Qdolo[®])</u>
<u>Antivirals, Topical</u>	<u>-acyclovir ointment (topical) -docosanol OTC</u>	<u>-Abreva OTC (topical) -Zovirax (topical)</u>

Manual Title	Chapter	Page
Pharmacy Manual	App. D	3
Chapter Subject	Page Revision Date	
Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, and Drug Utilization Review Board Service Authorization Changes	<u>TBD</u>	

	(topical)	
<u>Antimigraine, Other (NEW CLOSED CLASS)</u>	-Nurtec ODT	-Ubrelvy
<u>NSAIDs – oral Antipsychotics</u>	quetiapine ER	-quetiapine ER (AG) diclofenac pot (generic for Zipsor™)
<u>NSAIDs – topical COPD Agents</u>	-Spiriva Respimat	NA diclofenac 2% topical sol (generic for Pennsaid®)
<u>Rosacea Agents, Topical</u>		Epsolay®
<u>Sedatives/Hypnotics</u>		Quviviq™
<u>Cytokine and CAM Antagonists</u>	-Inflectra (IV)	-Renflexis (IV)
<u>Hypoglycemics, Insulins</u>	-insulin aspart cartridge/pen/vial -insulin aspart/insulin aspart protamine insulin pen/vial -insulin lispro Junior pen -insulin lispro pen -insulin lispro protamine mix pen	-Novolog Mix Pen/Vial
<u>SICKLE CELL ANEMIA TREATMENTS</u> <u>Hypoglycemics, Incretin Mimetics</u>	Droxia® Endari™ Oxbryta®	-Glyxambi Adakveo® Siklos®
<u>Simulants/ADHD Medications</u>	Dexmethylphenidate XR (generic for Focalin XR®)	Focalin XR®
<u>Multiple Sclerosis (NEW CLOSED CLASS)</u>	-dimethyl fumarate DR -dimethyl fumarate DR starter pack	-Tecfidera -Tecfidera Starter Pack
<u>Progestational agents (NEW CLOSED CLASS)</u>	NA	NA
<u>Stimulants</u>	-dexmethylphenidate	-Focalin
<u>Skeletal Muscle Relaxants</u>		Lyvispah™ Fleqsuvy™
<u>WEIGHT MANAGEMENT AGENTS</u>	Contrave® Qsymia® Saxenda® Xenical® Wegovy™	Incivree™

Classes in red designate Common Core Formulary “closed classes”
NEW CLOSED CLASSES

Manual Title	Chapter	Page
Pharmacy Manual	App. D	4
Chapter Subject	Page Revision Date	
Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, and Drug Utilization Review Board Service Authorization Changes	<u>TBD</u>	

AG = authorized generic

SA criteria can be found on the updated Preferred Drugs List (PDL/Common Core Formulary) at: <https://www.virginiamedicaidpharmacyservices.com/provider/preferred-drug-list>.

SA forms for specific drugs or drug classes can be found at: <https://www.virginiamedicaidpharmacyservices.com/provider/authorizations>

DRAFT

Manual Title	Chapter	Page
Pharmacy Manual	App. D	5
Chapter Subject	Page Revision Date	
Preferred Drug List / Common Core Formulary Changes, 90 Day Supply List Changes, and Drug Utilization Review Board Service Authorization Changes	<u>TBD</u>	

Virginia 90 day list changes Effective July <u>January 1, 2023</u>		
Drug Class	Added	Removed
COPD Agents <u>Sympatholytic Antihypertensives</u>	<u>Clonidine 0.1, 0.2, 0.3 mg/hr patches</u> Spiriva Respimat	NA <u>Catapres TTS® 0.1, 0.2, 0.3 mg/hr patches</u>
<u>Anticonvulsants</u>	<u>Carbatrol® ER 100, 200, 300mg cap</u> <u>Tegretol® XR 100, 200, 400mg tab</u> <u>Gabitril® 2, 4, 12, 16mg tab</u> <u>Lacosamide 50, 100, 150, 200 mg tabs</u> <u>Lacosamide 200 mg/20 ml sol</u> <u>Trileptal® 300mg/5 ml susp</u>	<u>Carbamazepine ER 100, 200, 300mg caps</u> <u>Carbamazepine ER 100, 200, 400 tabs</u> <u>Vimpat® 50, 100, 150, 200 mg tabs</u> <u>Vimpat® 200 mg/20 ml sol</u> <u>Oxcarbamazepine susp</u> <u>Olanzapine vial</u>
<u>Alzheimer's Disease Agents</u>	<u>Rivastigmine 4.6, 9.5, 13.3mg/24hr patch</u>	<u>Exelon® 4.6, 9.5, 13.3mg/24hr patch</u>
<u>Diabetes Agents</u>	<u>Invokamet® 50-500, 50-1000, 150-500, 150-1000 mg tab</u> <u>Pioglitazone 15, 30, 45 mg tab</u>	<u>Bydureon® 2mg</u>
<u>Proton Pump Inhibitors</u>	<u>Protonix® susp</u>	
<u>Respiratory Agents</u>	<u>Advair Diskus</u> <u>Pulmicort Flexhaler™</u>	<u>Bevespi®</u>
<u>Beta Blockers</u>		<u>Carvedilol ER 10, 20, 40, 80mg cap</u>
<u>Parkinson's Disease Agents</u>		<u>Pramipexole ER</u> <u>Ropinirole ER</u>
<u>Hypoglycemics, Insulins</u>	-insulin aspart cartridge/pen/vial -insulin aspart/insulin aspart protamine insulin pen/vial -insulin lispro junior pen -insulin lispro pen -insulin lispro protamine mix pen	-Novolog Mix Pen/Vial